Effectiveness and safety of finerenone in IgA nephropathy patients
Nephrology Dialysis Transplantation · 29.05.2026 · 41 (6) · 1129-1137
DOI: 10.1093/ndt/gfaf240 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 11.11.2025. Verfasst von Kuipeng Yu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Qilu Hospital of Shandong University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Angiotensin-Converting Enzyme Inhibitors, Naphthyridines, Angiotensin Receptor Antagonists. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Youth Foundation of Shandong Natural Science Foundation, ECCM Program of the Clinical Research Center of Shandong University.
Abstract (Originalsprache)
Background and hypothesis Immunoglobulin A nephropathy (IgAN) is the most common form of glomerulonephritis and a common cause of end-stage kidney disease. This study aimed to evaluate the effectiveness and safety of finerenone in combination with an angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker (ACEI/ARB) regimen in IgAN patients.
Methods
Our study was a single-center, observational, retrospective clinical study. Fifty-two primary IgAN patients were added. Patients were divided into two groups: the finerenone combined with ACEI/ARB group and the ACEI/ARB group. The primary endpoint was treatment response, defined as the percentage change in urinary protein/creatinine ratio (UPCR) and estimated glomerular filtration rate (eGFR) from baseline to 6 months. The secondary endpoint was the safety of finerenone, with adverse events recorded during treatment. Clinical data were collected from IgAN patients.
Results
Of the 52 IgAN patients enrolled, 19 were in the finerenone combined with ACEI/ARB group and 33 in the ACEI/ARB group. At 6 months, the percentage change in UPCR was significantly greater in the finerenone combined with ACEI/ARB group compared with the ACEI/ARB group [–52.10% (interquartile range, IQR –65.71%, –6.12%) vs –21.25% (IQR –39.84%, –6.19%); P = .04]. Furthermore, the UPCR was lower in the finerenone combined with ACEI/ARB group [0.41 g/g (IQR 0.30, 0.72) vs 0.68 g/g (IQR 0.49, 1.10); P = .024]. Serum albumin levels were higher in the finerenone combined with ACEI/ARB group than in the ACEI/ARB group (44.84 ± 2.35 g/L vs 42.96 ± 3.27 g/L; P = .033). No significant changes in eGFR were observed between the groups (P = .091). The response rate was significantly higher in the finerenone combined with ACEI/ARB group compared with the ACEI/ARB group (73.7% vs 39.4%, P = .017). No serious adverse events were observed in either group.
Conclusions
In real-world settings, the finerenone combined with ACEI/ARB regimen significantly improved outcomes in IgAN patients, effectively reducing proteinuria levels and increasing serum albumin levels, while maintaining relatively stable eGFR and exhibiting safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
- Department of Blood Purification, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Förderung
- Youth Foundation of Shandong Natural Science Foundation
- ECCM Program of the Clinical Research Center of Shandong University
Zitieren
APA
Yu, K., Li, D., Fan, X., Zhao, K., Wang, C., Bai, F., Liu, L., & Yang, X. (2026). Effectiveness and safety of finerenone in IgA nephropathy patients. Nephrology Dialysis Transplantation, 41(6), 1129-1137. https://doi.org/10.1093/ndt/gfaf240
Vancouver
Yu K, Li D, Fan X, Zhao K, Wang C, Bai F, et al. Effectiveness and safety of finerenone in IgA nephropathy patients. Nephrology Dialysis Transplantation. 2026;41(6):1129-1137. doi:10.1093/ndt/gfaf240
BibTeX
@article{Yu2026,
author = {Yu, Kuipeng and Li, Dengren and Fan, Xin and Zhao, Ke and Wang, Chunjie and Bai, Fang and Liu, Lei and Yang, Xiangdong},
title = {Effectiveness and safety of finerenone in IgA nephropathy patients},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
volume = {41},
number = {6},
pages = {1129--1137},
doi = {10.1093/ndt/gfaf240}
}
EUVIMED